drugset / Trial / NCT06393816
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review
Timeline
- Start
- 2024-06-13
- Primary completion
- 2028-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Etoposide | Small molecule | — | — |